Stay updated with breaking news from Janice Olson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ROYALSTON — The Friends of the Phinehas S. Newton Library will present the silent film “The Cabinet of Dr. Caligari” on Friday at 7 p.m. at the Town Hall, located at 19 On The Common.Directed by Robert Wiene, the 1920 German expressionist...
Groups whose mission is to help addicts recover from substance abuse still face many obstacles, a state drug and alcohol programs official said during a visit to Hempfield this week. Those obstacles may include establishing access to treatment, maintaining a workforce of recovery specialists and finding housing for those in
1.jpg)
Around the house: former GC for The New Yorker moves to Ballard Spahr 13 May 2021 Around the house: former GC for The New Yorker moves to Ballard Spahr This week's round of in-house appointments also sees ride-hailing giant Grab name a Skadden partner GC as it gears up for a record-setting SPAC merger Former First Look Media GC joins Ballard Spahr Noted First Amendment attorney Lynn Oberlander, whose CV includes the GC spot at The New Yorker and First Look Media, has begun a role as of counsel in the New York office of Am Law 100 firm Ballard Spahr. Oberlander has join...
Published: May 13, 2021 By Alex Keown Akouos, Inc. – Kathy Reape was named chief development officer of Boston-based Akouos. Reape most recently served as chief medical officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance, and medical affairs activities. Reape was a key member of the team responsible for the development and commercialization of Luxturna, the first FDA-approved in vivo gene therapy approved for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. Prior to Spark, Reape was senior vice president of clinic...
LogicBio Therapeutics Strengthens Management Team with Key Appointments - New leadership includes Andrea Paul as general counsel and corporate secretary, and Janice Olson as senior vice president, strategy and portfolio management, bringing extensive experience in gene therapy and rare disease News provided by Share this article Share this article LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulth...